research Erlotinib-Induced Skin Inflammation Is IL-1 Mediated in KC-Tie2 Mice and Human Skin Organ Culture
Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.
Search
for
Sort by
Research
30-60 / 1000+ results
research Oral Combination Treatment of Gefitinib (IressaTM) and Sasam-Kyeongokgo: Synergistic Effects on the NCI-H520 Tumor Cell Line
Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.
research Are all adverse effects undesirable? a case of chemotherapy induced adverse effect- an exception!?
Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
research Gefitinib-induced hair alterations: Figure 1
Gefitinib can cause slower, finer, brittle, and curly scalp hair.
research 증례 : Gefitinib에 의해 유발된 반흔성 탈모증
Gefitinib can cause rare scarring hair loss.
research An unusual terminal hair growth on the nose tip associated with gefitinib therapy
Gefitinib therapy can cause unusual hair growth on the nose.
research The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma
The combination of encorafenib and binimetinib caused few skin issues.
research Molecular Docking Studies and ADME Prediction of Novel Isatin Analogs with Potent Anti-EGFR Activity
Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.
research Hair Growth After Gefitinib Treatment
A man's bald spot grew hair after starting cancer treatment with gefitinib.
research Nilontinib induced keratosis pilaris atrophicans
Nilotinib can cause skin issues like red bumps and hair loss.
research Nilotinib-induced generalized keratosis pilaris: Report of a rare case
Nilotinib can cause generalized keratosis pilaris.
research Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib
Gefitinib can cause hair loss without scarring.
research Hair Re-Pigmentation After Nilotinib
Nilotinib may cause gray hair to return to its original color.
research Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
Gefitinib treatment led to unexpected hair growth in two lung cancer patients.
research Ivarmacitinib stimulates hair regrowth in severe alopecia areata
Ivarmacitinib effectively regrows hair in severe alopecia areata.
research Erlotinib-Associated Alopecia in a Lung Cancer Patient
Erlotinib can cause significant but temporary hair loss in lung cancer patients.
research Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
research A Case of Cicatricial Alopecia Associated with Erlotinib
Erlotinib can cause hair loss as a side effect.
research Multimodal therapeutic approach for a severe case of kaposiform lymphangiomatosis from procedural interventions to targeted therapies
Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.
research Delayed-onset pachyonychia congenita caused by a novel mutation in the V2 domain of keratin 6b
A new mutation in the K6b gene caused a girl's late-appearing nail condition.
research Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature
An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.
research Erlotinib induced acneiform eruption: A case report
Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.
research Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
research PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.
research Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
research Erlotinib-related Severe Hair Loss with Severe Exanthematous Drug Eruption: A Case Report
Stopping erlotinib improved severe hair loss and skin issues in a patient.
research Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
Afatinib often causes skin problems that need proactive management.
research Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.